News Events
November 2, 2010
Escape secures exclusive worldwide rights from Stanford University for a novel Botox formulation.
Escape signed an exclusive worldwide license agreement with Stanford University to commercialize novel patent-pending formulations of botulinum toxin with superior efficacy and side effect profiles compared to the commercially available form of botulinum toxin. Stanford University researchers have developed a method to improve the efficacy and accelerate the rate of onset of botulinum toxin treatment to relax hyperactive facial muscles and sweat glands by using a combination of a diffusion-limiting agent and botulinum toxin. Results of a 15-patient pilot study suggest that at least one of these formulations accelerated the rate of onset as well as the short-term efficacy of botulinum toxin for treatment of periorbital rhytides.